The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.
Patients with the coronavirus disease 2019 (COVID-19) have an altered faecal microbiome, characterized by enrichments in opportunistic pathogens, and depletions of beneficial commensals, according to a recent study.
While gastroesophageal reflux disease is a common comorbidity in idiopathic pulmonary fibrosis (IPF), treatment with a proton pump inhibitor does not appear to have any bearing on mortality and hospitalization outcomes among IPF patients, according to real-world data.
Vitamin D therapy and bariatric surgery in obese asthmatic patients both improve peripheral blood mononuclear cells (PBMC) sensitivity to the in vitro corticosteroid (CS) treatment, results of a Spain study have shown.
Asthma manifests differently between patients from urban and rural areas, likely due in part to differing environments, according to a recent study presented at the virtual International Congress 2020 of the European Respiratory Society (ERS 2020).
In children with asthma, genotype testing identifies a specific genetic alteration associated with poor response to long-acting β2 agonist (LABA), as shown in the PACT trial. This information proves useful in prescribing appropriate medications and improving asthma control.
Frequent coughing at night, measured using a smartphone app, appears to be a reliable indicator of worsening asthma, as reported in a study presented at this year’s European Respiratory Society (ERS) virtual meeting.
Adding selexipag to the double combination therapy of macitentan and tadalafil (triple combination) improved multiple outcomes in patients newly diagnosed with pulmonary arterial hypertension (PAH), results of the phase IIIb TRITON* trial showed.
Gefapixant, a first-in-class non-narcotic, oral P2X3 receptor antagonist, significantly reduces cough frequency in patients with refractory or unexplained chronic cough, according to two COUGH* studies presented at ERS 2020.
Almost three-quarters of adverse events (AEs) related to medication errors in over-the-counter (OTC) cough and cold medications (CCMs) for paediatrics required evaluation by healthcare facility and majority of the cases were due to dosing errors, a surveillance study has found, highlighting the need for interventions to mitigate medication errors.